In Brief: Becton Dickinson v. Quidel
This article was originally published in The Gray Sheet
Becton Dickinson v. Quidel: Firms reach settlement agreement on a patent infringement suit alleging that several Quidel products infringe on two Becton Dickinson patents for analytical chemistry tests ("The Gray Sheet" April 14, In Brief). Under the terms of the agreement Quidel will pay a cash license fee and royalties on net sales of the products beginning April 1, 1997. Quidel also will license its Q-Label technology to BD in exchange for royalties on future sales. Noting that it "has opportunities to mitigate the impact" of the additional expense through sales growth and improved margins, Quidel estimates that the annual cost of the settlement to the firm will be approximately $1.9 mil. Quidel continues to maintain that its products to not infringe the BD patents...
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.